Abstract
c-Myc is a nuclear protein with important roles in cell transformation, cell proliferation, and gene transcription. It has been previously shown that a 14-amino acid (aa) modified peptide (H1-S6A,F8A) derived from the helix 1 (H1) carboxylic region of c-Myc can interfere in vitro with specific c-Myc DNA binding. Here, we have linked the above Myc-derived 14-aa peptide to a 16-aa sequence from the third helix of Antennapedia (Int). It has been repeatedly reported that this 16-aa Antennapedia peptide is able to cross mammalian cell membranes and to work as a vector for short peptides.
Using fluorescent (dansylated or rhodaminated) peptides, we have shown that the fusion peptide with the Antennapedia fragment (Int-H1-S6A,F8A) but not the c-Myc derived fragment alone (H1-S6A,F8A) was capable of internalization inside MCF-7 human breast cancer cells. Int-H1-S6A,F8A and H1-S6A,F8A were the only two peptides capable of inhibiting coimmunoprecipitation of the c-Myc/Max heterodimer in vitro. We have treated (continuously for 10–11 days) MCF-7 cells with four different peptides: Int, H1-S6A,F8A, Int-H1-S6A,F8A, and Int-H1wt [a peptide differing from Int-H1-S6A,F8A by 2 aa (S6 and F8) in the H1 region]. In intact MCF-7 cells, Int-H1-S6A,F8A was the only active peptide capable of inducing the following biological effects: (a) inhibition of cloning efficiency on plates; (b) inhibition of cell growth and induction of apoptosis in subconfluent/confluent cells; and (c) inhibition of transcription of two c-Myc-regulated genes (ODC and p53). Int-H1-S6A,F8A was active in the 1–10 µm range.
Int-H1-S6A,F8A may represent a lead molecule for peptidomimetic compounds that have a similar three-dimensional structure but are more resistant to peptidases and, therefore, suitable for in vivo treatment of experimentally induced tumors.
Footnotes
-
↵1 This work was partially supported by grants from Associazione Italiana per la Ricerca sul Cancro (to P. R. and S. P.), the Italy-United States Program on “Therapy of Tumors” (to S. P.), the Programma Finalizzato Ministero della Sanità (to S. P.), and the Ministers Universita-Ricerca Scientifica e Tecnologica (MURST) Program [Programma Interuniversitario di Ricerca Scientifica (cofinanziamento MURST) ex 40%].
-
↵2 To whom requests for reprints should be addressed, at Department of Experimental Oncology, Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, Genoa 16132. Phone: 39-10-5600211; Fax: 39-10-5600210; E-mail: parodis@hp380.ist.unige.it.
- Received March 27, 1998.
- Accepted June 17, 1998.
- ©1998 American Association for Cancer Research.